These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 16953843

  • 1. Incretin mimetics as a novel therapeutic option for hepatic steatosis.
    Tushuizen ME, Bunck MC, Pouwels PJ, van Waesberghe JH, Diamant M, Heine RJ.
    Liver Int; 2006 Oct; 26(8):1015-7. PubMed ID: 16953843
    [Abstract] [Full Text] [Related]

  • 2. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.
    Sheffield CA, Kane MP, Busch RS.
    Pharmacotherapy; 2007 Oct; 27(10):1449-55. PubMed ID: 17896900
    [Abstract] [Full Text] [Related]

  • 3. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.
    Gallwitz B.
    Int J Clin Pract; 2006 Dec; 60(12):1654-61. PubMed ID: 17109672
    [Abstract] [Full Text] [Related]

  • 4. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
    Schwartz SL, Ratner RE, Kim DD, Qu Y, Fechner LL, Lenox SM, Holcombe JH.
    Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
    [Abstract] [Full Text] [Related]

  • 5. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.
    Samson SL, Sathyanarayana P, Jogi M, Gonzalez EV, Gutierrez A, Krishnamurthy R, Muthupillai R, Chan L, Bajaj M.
    Diabetologia; 2011 Dec; 54(12):3093-100. PubMed ID: 21956711
    [Abstract] [Full Text] [Related]

  • 6. Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance.
    Roden M.
    Nat Clin Pract Endocrinol Metab; 2006 Jun; 2(6):335-48. PubMed ID: 16932311
    [Abstract] [Full Text] [Related]

  • 7. Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series.
    Kenny PR, Brady DE, Torres DM, Ragozzino L, Chalasani N, Harrison SA.
    Am J Gastroenterol; 2010 Dec; 105(12):2707-9. PubMed ID: 21131943
    [No Abstract] [Full Text] [Related]

  • 8. Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial.
    Sofer E, Boaz M, Matas Z, Mashavi M, Shargorodsky M.
    Metabolism; 2011 Sep; 60(9):1278-84. PubMed ID: 21411114
    [Abstract] [Full Text] [Related]

  • 9. SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis.
    Xu F, Li Z, Zheng X, Liu H, Liang H, Xu H, Chen Z, Zeng K, Weng J.
    Diabetes; 2014 Nov; 63(11):3637-46. PubMed ID: 24947350
    [Abstract] [Full Text] [Related]

  • 10. [Exenatide--an incretin mimetic for treatment of diabetes mellitus type 2].
    Musch A, Heinzl S.
    Med Monatsschr Pharm; 2006 Mar; 29(3):86-9. PubMed ID: 16550880
    [No Abstract] [Full Text] [Related]

  • 11. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study.
    Nobili V, Manco M, Ciampalini P, Alisi A, Devito R, Bugianesi E, Marcellini M, Marchesini G.
    Clin Ther; 2008 Jun; 30(6):1168-76. PubMed ID: 18640473
    [Abstract] [Full Text] [Related]

  • 12. Current treatment of non-alcoholic fatty liver disease.
    Ahmed MH, Byrne CD.
    Diabetes Obes Metab; 2009 Mar; 11(3):188-95. PubMed ID: 18564173
    [Abstract] [Full Text] [Related]

  • 13. [Incretin-mimetic drugs, an insulin alternative in type 2 diabetes].
    Fabreegas B.
    Soins; 2008 Jun; (726):34-7. PubMed ID: 18697336
    [No Abstract] [Full Text] [Related]

  • 14. Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate.
    Forcheron F, Abdallah P, Basset A, del Carmine P, Haffar G, Beylot M.
    Obesity (Silver Spring); 2009 Jul; 17(7):1381-9. PubMed ID: 19553925
    [Abstract] [Full Text] [Related]

  • 15. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea.
    Mari A, Nielsen LL, Nanayakkara N, DeFronzo RA, Ferrannini E, Halseth A.
    Horm Metab Res; 2006 Dec; 38(12):838-44. PubMed ID: 17163361
    [Abstract] [Full Text] [Related]

  • 16. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
    Pinelli NR, Cha R, Brown MB, Jaber LA.
    Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626
    [Abstract] [Full Text] [Related]

  • 17. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease.
    Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ.
    Diabetes Metab Res Rev; 2006 Nov; 22(6):437-43. PubMed ID: 16832839
    [Abstract] [Full Text] [Related]

  • 18. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.
    Teranishi T, Ohara T, Maeda K, Zenibayashi M, Kouyama K, Hirota Y, Kawamitsu H, Fujii M, Sugimura K, Kasuga M.
    Metabolism; 2007 Oct; 56(10):1418-24. PubMed ID: 17884455
    [Abstract] [Full Text] [Related]

  • 19. Effects of a new sustained-release microsphere formulation of exenatide, DA-3091, on obese and non-alcoholic fatty liver disease mice.
    Son JP, Son MK, Jun SW, Kwak HH, Kang SH, Kang JS, Park YI.
    Pharmazie; 2013 Jan; 68(1):58-62. PubMed ID: 23444782
    [Abstract] [Full Text] [Related]

  • 20. Metformin reverses fatty liver disease in obese, leptin-deficient mice.
    Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM.
    Nat Med; 2000 Sep; 6(9):998-1003. PubMed ID: 10973319
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.